TWiV 1006: Clinical update with Dr. Daniel Griffin

This Week in Virology

Vincent Racaniello

Vincent, Microbe, Medicine, Microbiology, Racaniello, Infection, Virus, Virology, Pathogen, Infectious, Twiv, Science & Medicine

4.8 • 2.2K Ratings

🗓️ 13 May 2023

⏱️ 43 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

In his weekly clinical update, Dr. Griffin discusses immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age, influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults, COVID-19 surveillance after expiration of the public health emergency declaration, provisional mortality data, targeted vaccine messaging to promote COVID-19 vaccines for children and youth, vaccines and related biological products advisory committee meeting June 15, 2023 announcement, how to overhaul the CDC, impact of SARS-CoV-2 variants on inpatient clinical outcome, prevalence of post-coronavirus disease condition 12 weeks after Omicron infection compared with negative controls and association with vaccination status, gut bacteria cocktail helps long COVID, and gut microbiota‐derived symbiotic formula (SIM01) as a novel adjuvant therapy for COVID‐19. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Immunogenicity and tolerability of a bivalent norovirus vaccine in children (HVI) Influenza hemagglutinin stem nanoparticle vaccine induces neutralizing antibodies in healthy adults (STM) COVID-19 surveillance after expiration of the public health emergency declaration (CDC) Provisional mortality data (CDC) Targeted messaging to promote COVID-19 vaccines for children and youth (Pediatrics) Vaccines and biological products advisory committee meeting announcement (FDA) How to overhaul the C.D.C (NYTIMES) Impact of SARS-CoV-2 variants on inpatient clinical outcome (CID) Prevalence of post-COVID19 condition 12 weeks after Omicron infection and vaccination status (CID) Gut bacteria cocktail helps long COVID (MedPage) Gut microbiota‐derived synbiotic formula as a therapy for COVID‐19 (NIH) Contribute to our FIMRC fundraiser at PWB Letters read on TWiV 1006 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]

Transcript

Click on a timestamp to play from that location

0:00.0	This week in virology, the podcast about viruses, the kind that make you sick.
0:10.5	From micro TV, this is TWIV, this week in virology, episode 106 recorded on May 11th, 2023.
0:23.4	I'm Vincent Racken-Ello, and you're listening to the podcast, All About Viruses.
0:29.2	Joining me today from New York, Daniel Griffin. Hello, everyone. I made a point of saying,
0:35.4	1,000, six, because last time I said 1,000 and six and 1,000 and five, and I made a point of saying
0:42.4	I said it correctly, and when I heard it later, I realized I didn't. Okay, well let's get right
0:48.6	into it, you know, I think maybe we'll add a slogan, be nice to Vincent. It's okay. It's so hard
0:56.1	to forget pain, but it's even harder to remember sweetness. We have no scar to show for happiness,
1:02.2	and that's Margaret Atwoods, the Handmaid's Tale. I think we've gotten to a point where I'm
1:07.7	yeah, it's just a lot of, well, even that, you know, be nice to Vincent. Let's be a little more
1:13.4	gentler across the board, but we are getting, well, to the end of neurovirus winter vomiting disease,
1:21.2	maybe in a big way, a vaccine to prevent another experience trying to obtain natural immunity. No,
1:28.2	so the article immunogenicity and tower ability of a by-valent virus like particle neurovirus
1:35.2	vaccine candidate in children from six months to four years of age, a phase two randomized double
1:41.1	blind trial recently published in human vaccine immunotherapy. So early work, looking at anybody
1:47.6	response and safety, but some encouraging stuff, it would be great not to have to see
1:54.4	episode of look forward, dread winter vomiting disease in each year. Do we know what the correlates
2:01.2	of protection are? Are antibodies the whole story there? So that's that's going to be interesting
2:05.7	stuff that will come out of this. So there, there, this is early work looking at anybody response
2:10.7	and safety, but you know, what I really want to know is is efficacy does it work, and that's going
2:16.0	to help us come up with some good correlates here. Okay. In fluenza, the season has ended here in
2:22.6	the United States, but looking toward the future, we have the very exciting article, and I do think
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Vincent Racaniello, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Vincent Racaniello and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.